-
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
Thursday, July 21, 2022 - 2:15am | 361Biogen, Inc. (NASDAQ: BIIB) disclosed in its second-quarter earnings report that it recorded $900 million related to a settlement agreement to resolve previously disclosed "qui tam" litigation related to its conduct before 2015. Qui tam is a type of whistleblower...